AC Immune.
expertise in the understanding and treatment of neurodegeneration
- Reports this week
- 0
- Active events
- 0
- Connections
- 31
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
AC Immune's CEO sold 10,000 shares, and Jefferies Financial Group provided buy ratings and targets for the company.Some support1 report
-
AC Immune announced details regarding ongoing collaborations with Janssen and LILLY, led by CEO Andrea Pfeifer.Some support3 reports
-
The US market provides opportunities for biopharma companies, including AC Immune.Some support1 report
-
Zacks Investment Research downgraded three companies—Alexander's, AC Immune, and AmBev—to Strong Sell on August 6, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around AC Immune this week
News at the entities that move AC Immune most-
Johnson & Johnson StructuralCRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.Moves AC Immune
-
Vijay TransactionalVijay's personal wealth and property holdings in Chennai and Tamil Nadu have attracted public attention following his political career.Moves AC Immune
-
Jefferies Financial Group TransactionalFinancial firms including Truist, RBC, TD Cowen, and Jefferies issued various rating updates on October 30, 2026.Moves AC Immune
-
Boston StructuralTardy moved between Charleston and Boston on November 2, 2026.Moves AC Immune
-
FDA StructuralADC Therapeutics received accelerated approval for its drug from the FDA.Moves AC Immune
-
Nasdaq StructuralO’Reilly Automotive, Inc. traded on the Nasdaq exchange and filed required documents with the SEC on July 24, 2026.Moves AC Immune
Connections
The 12 strongest of 31, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Andrea Pfeifer Structural
Andrea Pfeifer holds the formal role of CEO of AC Immune.
-
Johnson & Johnson Structural
AC Immune collaborates with Johnson & Johnson on drug evaluation, with milestone payments triggered by trial progress.
-
Vijay Transactional
The individual's foundation provides necessary research funding for AC Immune's clinical trials.
-
Nasdaq Structural
AC Immune is a company that operates and trades on the Nasdaq stock exchange.
-
Boston Structural
AC Immune maintains a subsidiary in Boston.
-
Jefferies Financial Group Transactional
Jefferies Financial Group provides buy ratings and price targets for AC Immune.
-
FDA Structural
AC Immune is seeking review from the FDA regarding its Part 2 trial submission.
-
Europe Shared context
AC Immune is conducting Phase 1 clinical trials within the geographical boundaries of Europe.
Show all 12 connections
-
Lausanne Shared context
AC Immune is geographically based and operates within the city of Lausanne.
-
Switzerland Shared context
AC Immune is a company headquartered and operating within Switzerland.
-
London Shared context
AC Immune participated in a conference event held in London.
-
Cincinnati Mentioned together
No direct relationship or coupling between AC Immune and Cincinnati is supported by the evidence.
History
Events by the month they beganAugust 2026
1 eventJune 2026
5 events- AC Immune received research funding for clinical trials on June 11th.
- AC Immune's CEO sold 10,000 shares, and Jefferies Financial Group provided buy ratings and targets for the company.
- AC Immune announced details regarding ongoing collaborations with Janssen and LILLY, led by CEO Andrea Pfeifer.
- The US market provides opportunities for biopharma companies, including AC Immune.
- Zacks Investment Research downgraded three companies—Alexander's, AC Immune, and AmBev—to Strong Sell on August 6, 2025.